(Q36104945)

12 August 2017

1 reference

title

Secondary hormonal manipulations in prostate cancer. (English)

1 reference

12 August 2017

1 reference

2

Eric J Small

1 reference

12 August 2017

Charles J Ryan

1

1 reference

12 August 2017

publication date

1 May 2005

1 reference

12 August 2017

published in

Current Oncology Reports

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

228-233

1 reference

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone

12 August 2017

cites work

1 reference

12 December 2020

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

12 December 2020

Molecular determinants of resistance to antiandrogen therapy

1 reference

12 December 2020

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment

1 reference

12 December 2020

Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells

1 reference

12 December 2020

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

12 December 2020

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

12 December 2020

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

12 December 2020

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

12 December 2020

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

12 December 2020

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer

1 reference

12 December 2020

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

12 December 2020

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Studies on the human prostatic cancer cell line LNCaP.

1 reference

12 December 2020

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

12 December 2020

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

12 December 2020

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

1 reference

12 December 2020

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

1 reference

12 December 2020

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

1 reference

12 December 2020

Adrenalectomy and hypophysectomy for prostatic cancer

1 reference

12 December 2020

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

1 reference

12 December 2020

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

1 reference

12 December 2020

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

12 December 2020

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

1 reference

12 December 2020

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

12 December 2020

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

1 reference

12 December 2020

Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

12 December 2020

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

1 reference

12 December 2020

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

12 December 2020

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

10.1007/S11912-005-0078-X

Identifiers

DOI

1 reference

12 August 2017

1 reference